Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A critical analysis of the STEP-2 semaglutide trial in type 2 diabetes, covering enrollment biases, generalizability gaps, statistical caveats, conflict-of-interest disclosures, and post-publication commentary.
Read clinical reviewDeep-dive into published cost-effectiveness analyses of semaglutide 2.4 mg from the STEP-2 trial in type 2 diabetes, including cost per QALY, payer coverage, and real-world pricing.
Read clinical reviewWhat happened to weight loss after STEP-2 ended? Analysis of durability, weight regain, glycemic rebound, and long-term safety signals from semaglutide 2.4 mg in type 2 diabetes.
Read clinical reviewComplete breakdown of the STEP-2 trial results for semaglutide 2.4 mg in type 2 diabetes, including primary and secondary endpoints, confidence intervals, response distribution, and time-course data.
Read clinical reviewDeep-dive into STEP-2 pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg in type 2 diabetes, examining differential weight loss by age, sex, BMI, race, and baseline biomarkers.
Read clinical reviewA deep-dive overview of the STEP-2 randomized controlled trial testing semaglutide 2.4 mg for weight loss in adults with type 2 diabetes, including methodology, results, limitations, and clinical implications.
Read clinical reviewHow the STEP-2 trial reshaped prescribing for semaglutide 2.4 mg in type 2 diabetes, which guidelines responded, and what clinicians should consider for patients outside the trial population.
Read clinical review